Definium Therapeutics announced positive topline results from the Phase 3 Panorama study of DT120 ODT for generalized anxiety disorder (GAD). The trial met its primary endpoint, showing a placebo-adjusted reduction of 5.1 points in Hamilton Anxiety Rating Scale scores at Week 12 (p<0.0001) and significant improvements in key secondary endpoints. This marks the third positive Phase 3 readout for DT120 ODT, following successful studies in GAD and major depressive disorder. The company plans a pre-NDA meeting with the FDA in the fourth quarter of 2026 and anticipates filing a New Drug Application in the first half of 2027. Definium Therapeutics is a late-stage clinical biopharmaceutical company developing psychedelic-inspired therapeutics for psychiatric disorders.
